Michael S. Perry

CIK: 0001250379

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ARWR

ARROWHEAD PHARMACEUTICALS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Aug 18, 2026
Sale(S)
Direct
11.6K shares at avg. $87.30$1.0M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 16, 2025
Award(A)
Direct
7.8K shares-
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 5, 2025
Sale(S)
Direct
16.3K shares at avg. $61.03$992K
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 18, 2024
Award(A)
Direct
16.7K shares at avg. $22.99$385K

		Type	Shares	Price		Ownership
Aug 18, 2026	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Sale(S)	11,600	$87.30	$1,012,680	Direct
Dec 16, 2025	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Award(A)	7,819	-	-	Direct
Dec 5, 2025	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Sale(S)	16,250	$61.03	$991,738	Direct
Dec 18, 2024	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Award(A)	16,733	$22.99	$384,692	Direct

1-4 of 4 transactions

About PERRY MICHAEL S

PERRY MICHAEL S (SEC CIK 0001250379) files insider reports with the SEC as Director of ARROWHEAD PHARMACEUTICALS, INC. (ARWR).

Signal8 holds 4 ownership filings by PERRY MICHAEL S, all Form 4s, filed between Dec 20, 2024 and Aug 20, 2026. Those filings report 4 transactions, from Dec 18, 2024 to Aug 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on PERRY MICHAEL S's filings is in PASADENA, CA.

Recent filings by PERRY MICHAEL S

Aug 18, 2026: Open-market sale of ARWR shares (Form 4, code S).
Dec 16, 2025: Grant or award of ARWR shares (Form 4, code A).
Dec 5, 2025: Open-market sale of ARWR shares (Form 4, code S).
Dec 18, 2024: Grant or award of ARWR shares (Form 4, code A).

Other insiders filing for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

OLUKOTUN ADEOYE Y, Director
Cohen Matthew Gregory, Director
Lu Hongbo, Director
Apel Daniel Joseph, Chief Financial Officer
Hamilton James C, Chief Medical Officer
O'Brien Patrick, COO

How to read Form 4 transaction codes